Injectable,long-acting forms of risperdone and its metabolite have been approved for bipolar disorder and schizophrenia,respectively.

Question

Quizplus · Accepted Answer

This statement is true. Injectable, long-acting forms of risperidone (Risperdal Consta) have been approved for the treatment of bipolar disorder, while injectable, long-acting forms of its metabolite (Paliperidone Palmitate) have been approved for the treatment of schizophrenia.

Injectable,long-Acting Forms of Risperdone and Its Metabolite Have Been Approved